Dr. Zhu Chenggang received his undergraduate degree from Tsinghua University and his PhD from the University of California, Irvine School of Pharmacy. He has more than 10 years of industrial experience in the biopharmaceutical R&D industry. He has held key innovative drug discovery positions at Novartis and AstraZeneca, where he led several preclinical small molecule and biomolecule drug discovery projects and successfully advanced to clinical trials. He also holds more than 20 invention patents and has published more than 10 academic dissertations. He is a member of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO); he is a member of the Chinese Society of Clinical Oncology (CSCO).